Helmedix
Developing novel therapies for autoimmune and inflammatory diseases such as rheumatoid arthritis, colitis, psoriasis and multiple sclerosis.
Launch date
Employees
Market cap
-
Enterprise valuation
CAD4—7m (Dealroom.co estimates Feb 2013.)
Melbourne Victoria (HQ)
No columns specified